The only biotech with an active hESC-based clinical trial, Advanced Cell Technology (ACT) will have three top leaders including CEO Gary Rabin participating in a CIRM webinar on stem cell-based treatments for eye disorders this Wednesday. Also involved with be Samuel Barone, a medical officer from the FDA.
You don’t want to miss this one!
Register here (required in advance!)
I think CIRM and ACT joining forces on this is a great development.
(Hat tip to David Jensen, who posted on this yesterday)
I was looking at Dr Aron’s materials yesterday which are excellent and I attended the presentations today. They were excellent. I advise availing yourself of the option to revisit the video in about a week on the FDA site. I hope they do more of these as it outlines the level of research required for an IND…not easy but really no more than for a strict IRB. They also share how FDA will give pre pre IND conferences so that you know what is needed before applying and suggest going for these as soon as you decide o animal trials
For those interested, CIRM is using my two current stem cell tables as references (both are downloadable). One shows current stem therapy in ophthalmology by application and the other lists all of the companies and institutions active in using stem cells in ophthalmology..
Check out the website: http://cirm.ca.gov/Agenda_2012-05-02/regenerative-medicine-consortium